An A3 Executive Reference (2 pages) Japan rewards programs that are sequenced, evidenced, and locally socialized. […]
Cracking Japan’s Pharma Ecosystem: Field Notes from ~20 Years in the Trenches Japan rewards sequencing, proof, […]
As mRNA biotechnology matures, few firms have demonstrated a shift as dynamic as Moderna. Widely recognised […]
In the mid-1990s, Japan was not merely participating in the global pharmaceutical industry—it was shaping it. […]
Just now, AstraZeneca is making headlines with a $5.3 billion AI research partnership with China’s […]
Just before BioJapan 2025 takes over Pacifico Yokohama (Oct 8–10), another major event for diagnostics, JACLaS […]
Japan’s IVD sector remains highly structured and closely governed, benefiting from a mature healthcare infrastructure and […]
Japan is the fourth-largest global medical device market, with its healthcare system actively integrating digital tools […]
From Automation to Inflexion: AI’s Historical Trajectory in Pharma The pharmaceutical industry began its journey with […]
Some of Japan’s most forward-thinking minds gathered to scrutinise Japan’s biobank conundrum at Shonan iPark. In […]